Pharmacy

Experts say you should follow these 6 therapeutic areas.

The results of a large study of the impact of empagliflozin (Jardiance) on cardiovascular outcomes were recently published. Here are some key takeaways.

What are the top pharmacy challenges expected by healthcare executives in 2016 and what are they doing about it? Find out.

A new AARP report shows that the rapid rise in cost of specialty drugs exceeds median family income.

Traveling to Orlando for ASH 2015? Make the most out of your trip by attending these presentations. View the top 10.

New study results show that people with chronic HCV who inject drugs and are on opioid agonist therapy respond well to an investigational therapy.

A new Urban Institute study looks at the availability of antidepressants in marketplace insurance plans.

While many believe biosimilars have great potential, challenges remain.

New research raises questions on supposed cost savings drive by mail order pharmacies.

A senior clinical consultant at Express Scripts says it's critical for healthcare executives to keep an eye on recently approved specialty medications. Here are six to watch.

Study: Florida’s tougher drug laws and monitoring program is positively impacting opioid prevention efforts.

A senior clinical consultant at Express Scripts says it's critical for healthcare executives to keep an eye on how specialty medications in the pipeline will impact these four conditions.

How will the increasing number of approvals for specialty medications affect managed care? Aimee Tharaldson, of Express Scripts, weighs in.

Researchers from the Department of Pharmaceutical Sciences at the State University of New York at Buffalo highlight efforts to promote safe and appropriate use of opioids.

Traveling to Orlando for AMCP Nexus 2015? Make the most out of your trip by attending these presentations. View the top 10.

Raulo Frear, AMCP president, discusses the upcoming AMCP conference and some of the top challenges and opportunities facing the managed care pharmacy industry. Read more.

Several new drugs hold promise, but cost is a top concern.

The reasons for recent jumps in generic drug prices are varied, but some common themes have emerged in a new study by National Center for Policy Analysis Senior Fellow Devon Herrick.

Purchasers, manufacturers explore new pricing models

FDA’s approval of Vertex Pharmaceutical’s groundbreaking lumacaftor/ivacaftor (Orkambi) for cystic fibrosis (CF) is the first drug to treat the underlying cause of CF in people ages 12 and older with two copies of the F508del mutation.

A recent study projects that U.S. employers may see minimal savings to overall healthcare costs resulting from the introduction of biosimilars to the U.S. market.

Although prescription drug misuse is declining among teens, one in two patients tested between the ages of 10 and 17 years are not using their medications appropriately, potentially putting their health at risk, according to a new analysis.

Industry experts weigh the options between a traditional pharmacy benefits manager and a pharmacy benefits administrator.

The high cost of these medications could overwhelm patients and plans, according to one expert.

A health kiosk-decision support system may be a novel and important approach to improve provider prescription patterns.